Vascular Pharmacology
Vascular Pharmacology is a specialist journal of vascular biology and medicine, founded under its present title in 2002 and issued monthly by Elsevier. Its lineage runs back to Comparative and General Pharmacology of 1970, making it one of the longest-established titles in vascular pharmacology.《血管药理学》（Vascular Pharmacology）是一份聚焦血管生物学与血管医学的专科期刊，现刊名创刊于二〇〇二年，月刊发行，由爱思唯尔（Elsevier）出版。该刊刊脉上溯至一九七〇年的《比较与普通药理学》，是血管药理领域承接历史最久的刊物之一。
Scope
Vascular Pharmacology takes the blood vessel as the object of pharmacology and pathophysiology, its official scope organised along the spectrum of vascular disease and its methods spanning scales from biochemistry to gene editing. Its principal subject areas include:Vascular Pharmacology 的取稿立场是「以血管为对象的药理学与病理生理学」，官方范围说明按血管疾病谱系组织，方法学层面横跨从生化到基因编辑的多个尺度。收文范围覆盖的主要方向包括：
- Atherosclerosis and thrombosis: molecular and cellular mechanisms of atherosclerosis, thrombosis and haemostasis.动脉粥样硬化与血栓： 动脉粥样硬化、血栓形成与止血的分子与细胞机制。
- Metabolic vascular disease: mechanisms of vascular injury in diabetes, obesity and metabolic syndrome.代谢性血管病变： 糖尿病、肥胖与代谢综合征中的血管损伤机制。
- Vascular remodelling and injury: vascular ageing, repair and regeneration, reperfusion injury, and transplant arteriopathy.血管重构与损伤： 血管衰老、修复与再生，缺血再灌注损伤，以及移植血管病变。
- Special vascular beds: pulmonary hypertension, neurovascular diseases and microvascular dysfunction.特殊血管床： 肺循环高压、神经血管疾病与微血管功能障碍。
- Oncology and immunology: cardiovascular toxicity of anticancer drugs, and immunological influences in vascular disease.肿瘤与免疫： 抗肿瘤药物的心血管毒性，以及免疫因素在血管疾病中的作用。[1]
History
- Lineage begins (1970): the journal's lineage begins with Comparative and General Pharmacology (1970-1974), renamed General Pharmacology in 1975 and carrying the subtitle The Vascular System from 1999.刊脉起点（一九七〇年）： 本刊刊脉始于《比较与普通药理学》（一九七〇至一九七四年），一九七五年改名《普通药理学》，一九九九年起加副题「血管系统」。[2]
- Present title adopted (2002): the present title Vascular Pharmacology was adopted in 2002, with volume numbering continuing from thirty-eight, published by Elsevier Science in New York.启用现名（二〇〇二年）： 二〇〇二年启用现名 Vascular Pharmacology，卷号自第三十八卷接续，由爱思唯尔科学公司在纽约出版。[3]
- Publisher transition: the predecessor titles were published by Pergamon Press, and the journal has been published by Elsevier since 2002出版方沿革： 前身刊由佩加蒙出版社出版，现刊自二〇〇二年起由爱思唯尔出版并延续至今；本刊无学会背景。 it has no society affiliation.[2]
- Metric standing: the 2025 impact factor is 3.7, placing the journal in the second quartile of pharmacology and pharmacy, with recent years in zone three of medicine in the Chinese Academy of Sciences ranking.指标走势： 二〇二五年影响因子三点七，在药学与药学小类列二区，近年在中科院医学大类列三区。[4]
Editors
The journal operates under an editor-in-chief with a senior associate editor, five consulting editors, an associate editor and a full complement of early-career, social media and statistical editors, one hundred and twenty-four editors and board members in all across thirteen countries. Elsevier's official 2025 figures give six days from submission to first decision, including editorial desk review, thirty-one days to a decision after review, sixty-eight days to acceptance and two days from acceptance to online publication本刊实行主编统筹的编辑架构，配一名资深副编辑、五名顾问编辑、一名副编辑及涵盖早期职业学者、社交媒体编辑与统计编辑的完整班子，编辑及编委共一百二十四人、分驻十三国。二〇二五年爱思唯尔官方指标显示：投稿至首次决定六天（含编辑部桌审）、复审后决定三十一天、投稿至录用六十八天、录用至两天在线发表；出版方未公布录用率。 no acceptance rate is published.[5]
- Joseph Miano (editor-in-chief): professor of medicine at Augusta University in the United States and holder of the J. Harold Harrison Distinguished University Chair in Vascular Biology, working on genetically engineered mouse models and gene regulation in vascular smooth muscle cells.约瑟夫·米亚诺（现任主编）： 美国奥古斯塔大学医学教授、哈罗德·哈里森血管生物学讲席教授，研究方向为基因工程小鼠模型与血管平滑肌细胞基因调控。[5]
- Raffaele De Caterina and John D. Catravas (immediate past editors): the two edited the journal in succession, with Clinton Webb before them拉法埃莱·德·卡泰里纳与约翰·卡特拉瓦斯（前任主编）： 二人先后执掌本刊，更早一任为克林顿·韦布；编委层中顾问编辑阵容涵盖彼得·利比等动脉粥样硬化研究名家。 the consulting-editor layer includes such figures of atherosclerosis research as Peter Libby.[5]